Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide

Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities.

More here:
Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide

Related Posts